Metropolis Healthcare I BUY

JM FINANCIAL

Ripe for a rally

Core business revenue (ex-Covid, ex-PPP) grew 12% YoY (1% impact on account of floods) with 9% volume growth (key positive). B2C business continues to deliver strong mid-teens growth, particularly driven by core markets such as Mumbai (18%). Reported EBITDAM of 22.3% includes 0.8% impact of provision for Mohalla clinics business and 1.4% dilution on account of NACO contract expiry. Over the next 3 years, we expect a mid-teens revenue CAGR with meaningful margin expansion (to 27%) supported by price hikes, PPP base reset and network expansion. Receding competitive intensity, near-completion of accelerated network expansion, robust Hitech performance, sustained volume growth, base reset and improving earnings visibility build a compelling case for our 'BUY' thesis. We value METROHL at 42x Dec'25 earnings (near 5Y average) to derive a TP of INR 1,865. In our view, METROHL is now ripe for a rally and prefer it as our 'top pick' in the diagnostics sector.

- We prefer METROHL as our 'top pick' in the diagnostic sector: We expect 14-15% revenue CAGR over the next 3 years along with margin expansion (to 27%). METROHL's 3Q earnings were subdued due to NACO contract expiry, aggressive network addition and provision for Mohalla clinics business (0.8% margin impact). We believe earnings have bottomed out and B2C price hikes w.e.f. Jan'24 and B2B specialised segment price hikes w.e.f. 1QFY25 will drive strong operating leverage. The management alluded to 26-27% FY25 margins, in line with pre-Covid levels. Lab expansion will continue (30 lab expected to be added next year as well), post which operating leverage will be realised. Core volume growth remains healthy at 9% with B2C, specialised and Hitech franchise performing well. METROHL, with network expansion cycle almost at the end, sustained volume growth, base reset and price hikes across portfolio builds a case for re-rating.
- Revenue momentum to accelerate: Metropolis' revenue increased 2%YoY to INR 2.9bn (in line), optically subdued due to expiry of the NACO contract and part impact of Tamil Nadu floods. Core business revenue (ex-PPP, ex-Covid) grew 13%YoY. B2C revenue outpaced overall growth at 15% YoY with Mumbai growing faster (18%). Core business patient volume increased to 2.8mn (+9% YoY) and ARPP grew ~3% YoY to INR 1009. Premium wellness tests' share was 15% of revenue (vs. 14% YoY), growing 15% YoY (11% volume growth).
- Network expansion on track: Metropolis is on course to add 90 labs and 1,800 service centres over FY21-25. This will be via increasing penetration in focus markets and widening geographical presence (595 towns as of 9MFY24) in untapped markets. The company plans to deepen its presence in Chennai and Bengaluru, akin to Mumbai. It will add 30 labs in FY25. During 9MFY24, Metropolis (ex Hitech) added 17 labs and 400 centres across geographies, leading to margin dilution of 120bps (+40bps YoY). METROHL plans to introduce basic radiology services (ECG, X-Ray etc.) in its 400 owned centres to increase ARPP as the services are complementary to its current offering. These services will be provided through an asset light model and are not expected to dilute margins.

Financial Summary					(INR mn)
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
Net Sales	12,283	11,482	11,862	13,526	15,429
Sales Growth (%)	23.1	-6.5	3.3	14.0	14.1
EBITDA	3,428	2,883	2,799	3,503	4,166
EBITDA Margin (%)	27.9	25.1	23.6	25.9	27.0
Adjusted Net Profit	1,983	1,429	1,297	1,900	2,397
Diluted EPS (INR)	38.8	27.9	25.4	37.1	46.9
Diluted EPS Growth (%)	7.8	-27.9	-9.2	46.5	26.1
ROIC (%)	32.9	15.8	14.7	20.4	26.5
ROE (%)	24.9	15.2	12.6	16.6	18.7
P/E (x)	42.2	58.6	64.6	44.1	34.9
P/B (x)	9.4	8.5	7.8	6.9	6.2
EV/EBITDA (x)	24.6	28.9	29.3	23.0	18.9
Dividend Yield (%)	0.5	0.3	0.4	0.6	0.9

Source: Company data, JM Financial. Note: Valuations as of 02/Feb/2024

Amey Chalke amey.chalke@jmfl.com | Tel: (91 22) 66303056 Jainil Shah

jainil.shah@jmfl.com | Tel: (91 22) 66303155

Raghav Vedanarayanan

raghav.vedanarayanan@jmfl.com | Tel: (91 22) 62241851

Recommendation and Price Targe	t
Current Reco.	BUY
Previous Reco.	BUY
Current Price Target (12M)	1,865
Upside/(Downside)	13.9%
Previous Price Target	1,635
Change	14.1%
Key Data – METROHL IN	
Current Market Price	INR1,637

Current Market Price	INR1,637
Market cap (bn)	INR83.9/US\$1.0
Free Float	44%
Shares in issue (mn)	50.9
Diluted share (mn)	51.2
3-mon avg daily val (mn)	INR657.5/US\$7.9
52-week range	1,755/1,171
Sensex/Nifty	72,086/21,854
INR/US\$	82.9

Price Performance %	1M	6M	12M
Absolute	-3.5	20.5	33.7
Relative*	-3.5	9.8	12.9

* To the BSE Sensex


JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this See Capital IQn FractSection Discribion and Discribion and Discribion and Discribion and Discrimination a

Please see Appendix I at the end of this report for Important Disclosures and

Metropolis Healthcare


Key financials: Revenue/EBITDA/PAT of INR 2.9bn/ 648mn/ 272mn grew +2%/-8%/-24% YoY and were in line/-5%/-17% vs. our estimates. Gross margin improved c. 270bps YoY to 80.3% (JMFe: 79.6%). EBITDA margin declined c.240bps YoY to 22.3% (JMFe: 23.5%). This includes an impact of INR 22mn pertaining to provision for doubtful debts related to the delay in receiving dues from the Delhi government for the Mohalla clinic project. The company has gross debt of INR 127mn and plans to be debt-free by the end of the year. At present, the company has a cash balance of INR 890mn.



Source: Bloomberg


Exhibit 2. We expect METROHL to outperform DLPL over the next 3 years					
DLPL	METROHL				
12%	15%				
13%	20%				
17%	31%				
	DLPL 12% 13%				

Source: JM Financial



4500

Exhibit 4. Aggressive service network expansion




Source: Company, JM Financial

Source: Company, JM Financial

5000

4355



Source: Company, JM Financial

Metropolis - P&L (INR mn)	3QFY23A	3QFY24A	% YoY	3QFY24E	% Delta vs JMFe	Y24E (cons)	% Delta vs cons	2QFY24A	% QoC
Total Revenue	2,855	2,911	2%	2,910	0%	2,930	-1%	3,085	-6%
COGS	639	572	-10%	594	-4%			613	-7%
Gross Profit	2,216	2,339	6%	2,316	1%			2,472	-5%
Gross Profit margin (%)	77.6%	80.3%	272 bps	79.6%	73 bps			80.1%	19 bp:
Staff Cost	646	695	8%	672	3%			698	0%
Other expenses	865	995	15%	960	4%			1,027	-3%
EBITDA	705	648	-8%	684	-5%	709	-9%	748	-13%
EBITDA margin (%)	24.7%	22.3%	-242 bps	23.5%	-122 bps			24.2%	-197 bps
Other Income	66	23	-65%	25	-8%			12	89%
Finance Cost	61	53		50				57	
Depreciation	230	250		215				222	
РВТ	480	369	-23%	444	-17%			481	-23%
Exceptional Items	0	0		0				(33)	
Tax	121	96		115				125	
Tax Rate (%)	25.2%	26.0%		26.0%				27.8%	
Minority Interest	1	1		1				2	
PAT (Reported)	358	272	-24%	327	-17%	340	-20%	355	-23%
PAT (Adjusted)	358	272		327				388	-30%
EPS (Reported)	7	5	-24%	6	-17%			7	-23%
EPS (Adjusted)	7	5		6				8	-30%
Metropolis - Cost margins	3QFY23A	3QFY24A	% YoY	3QFY24E	% Delta vs JMFe			2QFY24A	% QoQ
COGS/sales	22.4%	19.7%	-272 bps	20.4%	-73 bps			19.9%	-19 bps
Staff cost/sales	22.6%	23.9%	125 bps	23.1%	78 bps			22.6%	126 bps
Other expenditure/sales	30.3%	34.2%	388 bps	33.0%	118 bps			33.3%	90 bps

Financial Tables (Consolidated)

Income Statement				(INR mn)
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
Net Sales	12,283	11,482	11,862	13,526	15,429
Sales Growth	23.1%	-6.5%	3.3%	14.0%	14.1%
Other Operating Income	0	0	0	0	C
Total Revenue	12,283	11,482	11,862	13,526	15,429
Cost of Goods Sold/Op. Exp	2,760	2,533	2,384	2,705	3,086
Personnel Cost	2,332	2,527	2,740	3,043	3,394
Other Expenses	3,763	3,539	3,938	4,274	4,783
EBITDA	3,428	2,883	2,799	3,503	4,166
EBITDA Margin	27.9%	25.1%	23.6%	25.9%	27.0%
EBITDA Growth	19.9%	-15.9%	-2.9%	25.1%	18.9%
Depn. & Amort.	632	892	914	936	945
EBIT	2,796	1,991	1,885	2,567	3,220
Other Income	176	152	96	196	242
Finance Cost	197	268	221	189	217
PBT before Excep. & Forex	2,775	1,875	1,759	2,575	3,246
Excep. & Forex Inc./Loss(-)	159	0	0	0	C
PBT	2,934	1,875	1,759	2,575	3,246
Taxes	787	441	457	669	844
Extraordinary Inc./Loss(-)	0	0	0	0	C
Assoc. Profit/Min. Int.(-)	-5	-5	-5	-5	-5
Reported Net Profit	2,142	1,429	1,297	1,900	2,397
Adjusted Net Profit	1,983	1,429	1,297	1,900	2,397
Net Margin	16.1%	12.4%	10.9%	14.0%	15.5%
Diluted Share Cap. (mn)	51.2	51.2	51.2	51.2	51.2
Diluted EPS (INR)	38.8	27.9	25.4	37.1	46.9
Diluted EPS Growth	7.8%	-27.9%	-9.2%	46.5%	26.1%
Total Dividend + Tax	409	339	405	594	899
Dividend Per Share (INR)	8.0	5.3	6.3	9.3	14.1

Balance Sheet				((INR mn)
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
Shareholders' Fund	8,862	9,882	10,774	12,080	13,613
Share Capital	102	102	102	102	102
Reserves & Surplus	8,760	9,780	10,671	11,978	13,511
Preference Share Capital	0	0	0	0	0
Minority Interest	20	25	30	35	35
Total Loans	2,585	791	0	0	0
Def. Tax Liab. / Assets (-)	769	713	713	713	713
Total - Equity & Liab.	12,236	11,411	11,517	12,829	14,362
Net Fixed Assets	9,552	9,668	9,353	9,067	8,501
Gross Fixed Assets	4,339	4,996	5,596	6,246	6,576
Intangible Assets	8,280	8,610	8,610	8,610	8,660
Less: Depn. & Amort.	3,067	3,938	4,853	5,789	6,735
Capital WIP	0	0	0	0	0
Investments	155	148	148	148	148
Current Assets	5,498	5,131	5,518	7,608	10,268
Inventories	511	446	494	563	642
Sundry Debtors	1,355	1,219	1,308	1,492	1,702
Cash & Bank Balances	1,669	932	1,269	2,762	4,741
Loans & Advances	115	141	136	155	177
Other Current Assets	1,847	2,394	2,312	2,636	3,007
Current Liab. & Prov.	2,969	3,536	3,503	3,994	4,556
Current Liabilities	1,867	2,201	2,214	2,524	2,880
Provisions & Others	1,102	1,335	1,289	1,470	1,677
Net Current Assets	2,529	1,595	2,016	3,614	5,712
Total – Assets	12,236	11,411	11,517	12,829	14,362

Source: Company, JM Financial

Source: Company, JM Financial

Cash Flow Statement				(INR mn)
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
Profit before Tax	2,934	1,875	1,759	2,575	3,246
Depn. & Amort.	632	892	914	936	945
Net Interest Exp. / Inc. (-)	72	211	125	-8	217
Inc (-) / Dec in WCap.	-164	71	-83	-105	-120
Others	-116	-63	0	0	0
Taxes Paid	-825	-516	-457	-669	-844
Operating Cash Flow	2,533	2,471	2,259	2,729	3,445
Capex	-307	-526	-600	-650	-330
Free Cash Flow	2,226	1,945	1,659	2,079	3,115
Inc (-) / Dec in Investments	-7,180	929	96	196	151
Others	111	65	0	0	0
Investing Cash Flow	-7,376	468	-504	-454	-179
Inc / Dec (-) in Capital	0	0	0	0	0
Dividend + Tax thereon	-409	-410	-405	-594	-899
Inc / Dec (-) in Loans	2,585	-1,789	-791	0	0
Others	-538	-712	-221	-189	-217
Financing Cash Flow	1,637	-2,910	-1,417	-782	-1,116
Inc / Dec (-) in Cash	-3,206	29	337	1,493	2,150
Opening Cash Balance	3,866	660	688	1,026	2,519
Closing Cash Balance	660	688	1,026	2,519	4,668

Source: Company, JM Financial

Dupont Analysis					
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
Net Margin	16.1%	12.4%	10.9%	14.0%	15.5%
Asset Turnover (x)	1.2	0.9	0.9	1.0	1.0
Leverage Factor (x)	1.3	1.4	1.2	1.2	1.2
RoE	24.9%	15.2%	12.6%	16.6%	18.7%

Key Ratios					
Y/E March	FY22A	FY23A	FY24E	FY25E	FY26E
BV/Share (INR)	173.3	193.2	210.6	236.2	266.1
ROIC	32.9%	15.8%	14.7%	20.4%	26.5%
ROE	24.9%	15.2%	12.6%	16.6%	18.7%
Net Debt/Equity (x)	0.1	0.0	-0.1	-0.2	-0.4
P/E (x)	42.2	58.6	64.6	44.1	34.9
P/B (x)	9.4	8.5	7.8	6.9	6.2
EV/EBITDA (x)	24.6	28.9	29.3	23.0	18.9
EV/Sales (x)	6.9	7.2	6.9	6.0	5.1
Debtor days	40	39	40	40	40
Inventory days	15	14	15	15	15
Creditor days	43	40	40	41	42

Source: Company, JM Financial

Metropolis Healthcare

1.12

History of Recommendation and Target Price								
Date	Recommendation	Target Price	% Chg.					
4-Jul-22	Buy	1,760						
11-Aug-22	Buy	1,700	-3.4					
9-Nov-22	Buy	1,895	11.5					
13-Feb-23	Buy	1,825	-3.7					
3-Mar-23	Buy	1,775	-2.7					
17-May-23	Buy	1,670	-5.9					
3-Aug-23	Buy	1,610	-3.6					
6-Nov-23	Buy	1,635	1.6					

1.0.2

Recommendation History Metropolis Healthcare 3600 3060 2520 1980 В В B BB 1440 900 Aug-22 Aug-23 Feb-21 Aug-21 Feb-22 Feb-23 Feb-24 Taget Price Price -

JM Financial Institutional Securities Limited

APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: sahil.salastekar@jmfl.com

Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of ratings	
Rating	Meaning
Buy	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., <u>JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 28th Floor, Office No. 2821, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.</u>

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.